Compare Bristol-Myers Squibb Co (BMY) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs ABRDN Physical Gold Shares ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while ABRDN Physical Gold Shares ETF trades at $41.98. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while ABRDN Physical Gold Shares ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| BMY | SGOL | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $65.89 | $51.41 |
52-Week Low | $42.60 | $31.61 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
SGOL trades at $42.21, up 0.98% with a bullish technical signal from moving averages, though oscillators show caution with RSI at overbought levels. The gold ETF benefits from recent CPI data showing cooling inflation and strong central bank demand, with spot gold prices testing key resistance levels. Financial ratios remain unavailable for this commodity-focused ETF structure.
The outlook remains positive given gold's momentum and macroeconomic support, though overbought conditions suggest potential near-term consolidation. Key risks include Fed policy shifts and dollar strength, while institutional buying provides underlying support for the gold thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
